4026 The Efficacy and Safety of Peanut Oral Immunotherapy in High-Dose with Predicting Factors

Saturday, 17 October 2015
Hall D1 Foyer (Floor 3) (Coex Convention Center)

Ishaq M, MD PhD , Pulmonology, Al-Junaid Medical Center Kpk, Nowshera, Pakistan

Sameera MI Khan, MD , Consultant Inova, Alexandria, VA

Imran Khan , Unknown, Cardiac Care Center, Falls Church, VA

Sabeen Khan , George Washington Hospital, Washington DC, DC


Is to test the efficacy and safety of a novel oral immunotherapy (OIT) protocol for peanut allergy.


In  the  study concerned, Forty  peanut-allergic children (mean age 10 years) had  oral allergen preparation. This was administered with serial rising titers and dosing at about 2 weekly to 850 mg peanut protein. There was maintenance of 28 weeks.


All children had positive challenges. Of the total, 30 had tolerated the rising concentration of the titer. 2 of the total then dropped out, while 4 out of the total had tolerated the rising concentration of the allergenic material containing 250mg -500 mg. Some 30 out of 40 tolerated higher dosing and maintenance at 850 mg protein/day.

Two had some severe degree of allergenic reaction mandating the administration of adrenaline, whereas the rest had mild allergic reaction that subsided without resorting to adrenaline solution. Twelve with pre-immunotherapy peanut IgE over 28.3 kU/L required no dose adjustment compared with  7  with pre-immunotherapy peanut IgE level almost 27. kU/L. Eighteen of the 40  mandated a slight dose reduction as  the reactions possibly linked to factors, such as  exertion, infection and fatigue ability . However after 7 weeks, 25 out of  40 individuals had no reaction to a 2.7 g protein challenge.


This study with serial dilution and dose increments  has  been followed with better outcome than the former trials. A higher fold such as 1000 and over in the amount of peanuts is tolerated with excellent safety profiles. Except a few cases there was no serious adverse effects observed in the rest of individuals.